The role of chemotherapy in cholangiocarcinoma.

PubWeight™: 1.46‹?› | Rank: Top 5%

🔗 View Article (PMID 15958484)

Published in Ann Oncol on January 01, 2005

Authors

S Thongprasert1

Author Affiliations

1: Division of Medical Oncology, Department of Medicine, Faculty of Medicine, Chiang Mai, University, Chiang Mai, Thailand.

Associated clinical trials:

Gemcitabine and S-1 for Advanced Biliary Tract Cancer | NCT02146703

Articles citing this

Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009. World J Gastroenterol (2009) 2.17

Cytotoxic activity of Thai medicinal plants against human cholangiocarcinoma, laryngeal and hepatocarcinoma cells in vitro. BMC Complement Altern Med (2010) 1.31

Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer (2010) 1.04

Establishment and characterization of a cholangiocarcinoma cell line (RMCCA-1) from a Thai patient. World J Gastroenterol (2006) 0.96

Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report. BMC Cancer (2006) 0.95

Surgery and chemotherapy for intrahepatic cholangiocarcinoma. World J Hepatol (2010) 0.94

CEACAM6 gene expression in intrahepatic cholangiocarcinoma. Br J Cancer (2006) 0.94

Nervous and Neuroendocrine regulation of the pathophysiology of cholestasis and of biliary carcinogenesis. World J Gastroenterol (2006) 0.91

Gemcitabine with carboplatin for advanced biliary tract cancers: a phase II single institution study. HPB (Oxford) (2010) 0.91

FTY720 inhibits proliferation and epithelial-mesenchymal transition in cholangiocarcinoma by inactivating STAT3 signaling. BMC Cancer (2014) 0.89

Radiotherapy and chemotherapy as therapeutic strategies in extrahepatic biliary duct carcinoma. Strahlenther Onkol (2010) 0.89

Inhibition of histone deacetylase for the treatment of biliary tract cancer: a new effective pharmacological approach. World J Gastroenterol (2007) 0.87

Adjuvant transcatheter arterial chemoembolization for intrahepatic cholangiocarcinoma after curative surgery: retrospective control study. World J Surg (2011) 0.87

c-Met targeted therapy of cholangiocarcinoma. World J Gastroenterol (2008) 0.86

Array comparative genomic hybridization identifies novel potential therapeutic targets in cholangiocarcinoma. HPB (Oxford) (2011) 0.86

FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma. World J Gastroenterol (2015) 0.86

Photodynamic therapy: Palliation and endoscopic technique in cholangiocarcinoma. World J Gastrointest Endosc (2010) 0.85

Palliative hepatic intraarterial chemotherapy (HIC) using a novel combination of gemcitabine and mitomycin C: results in hepatic metastases. Eur Radiol (2007) 0.84

Vincristine enhances amoeboid-like motility via GEF-H1/RhoA/ROCK/Myosin light chain signaling in MKN45 cells. BMC Cancer (2012) 0.84

Prevalence of known and unknown primary tumor sites in spinal metastasis patients. Open Orthop J (2012) 0.84

C-reactive protein is a prognostic indicator in patients with perihilar cholangiocarcinoma. World J Gastroenterol (2006) 0.83

Prognosis of the intrahepatic cholangiocarcinoma after resection: hepatitis B virus infection and adjuvant chemotherapy are favorable prognosis factors. Cancer Cell Int (2013) 0.83

Photodynamic therapy for cholangiocarcinoma. Gut Liver (2010) 0.82

Trans-arterial embolisation therapies for unresectable intrahepatic cholangiocarcinoma: a systematic review. J Gastrointest Oncol (2015) 0.82

Prognostic factors in patients with advanced cholangiocarcinoma: role of surgery, chemotherapy and body mass index. World J Gastroenterol (2008) 0.81

Establishment of a novel orthotopic xenograft model of human gallbladder carcinoma. Clin Exp Metastasis (2007) 0.81

Radiofrequency ablation for postoperative recurrences of intrahepatic cholangiocarcinoma. Chin J Cancer Res (2011) 0.81

Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer. Transl Oncol (2015) 0.80

Orotate phosphoribosyl transferase mRNA expression and the response of cholangiocarcinoma to 5-fluorouracil. World J Gastroenterol (2012) 0.78

Perioperative Management of Hilar Cholangiocarcinoma. J Gastrointest Surg (2015) 0.77

Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer. BMC Cancer (2015) 0.76

Antitumor effect of forbesione isolated from Garcinia hanburyi on cholangiocarcinoma in vitro and in vivo. Oncol Lett (2016) 0.76

Synergistic effects of isomorellin and forbesione with doxorubicin on apoptosis induction in human cholangiocarcinoma cell lines. Cancer Cell Int (2014) 0.76

Chemotherapy for advanced biliary tract carcinoma: A meta-analysis of randomized controlled trials. Medicine (Baltimore) (2016) 0.75

Synergistic antitumor activity of the combination of salubrinal and rapamycin against human cholangiocarcinoma cells. Oncotarget (2016) 0.75

Kaempferol inhibits the growth and metastasis of cholangiocarcinoma in vitro and in vivo. Acta Biochim Biophys Sin (Shanghai) (2016) 0.75

Middle bile duct cancer with portal vein tumor thrombus. World J Surg Oncol (2008) 0.75

miR-106b regulates the 5-fluorouracil resistance by targeting Zbtb7a in cholangiocarcinoma. Oncotarget (2017) 0.75